[HTML][HTML] Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
The mammalian target of rapamycin (mTOR) is a protein kinase that controls cellular
metabolism, catabolism, immune responses, autophagy, survival, proliferation, and …
metabolism, catabolism, immune responses, autophagy, survival, proliferation, and …
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
[HTML][HTML] Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Abstract The PI3K-Akt-mechanistic (formerly mammalian) target of the rapamycin (mTOR)
signaling pathway is important in a variety of biological activities, including cellular …
signaling pathway is important in a variety of biological activities, including cellular …
[HTML][HTML] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis …
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
AJ Armstrong, S Halabi, T Eisen, S Broderick… - The Lancet …, 2016 - thelancet.com
Background Non-clear cell renal cell carcinomas are histologically and genetically diverse
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …
Targeting the phosphoinositide 3-kinase pathway in cancer
P Liu, H Cheng, TM Roberts, JJ Zhao - Nature reviews Drug discovery, 2009 - nature.com
Abstract The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system
that links oncogenes and multiple receptor classes to many essential cellular functions, and …
that links oncogenes and multiple receptor classes to many essential cellular functions, and …
Renal cell carcinoma
BI Rini, SC Campbell, B Escudier - The Lancet, 2009 - thelancet.com
Considerable progress has been made in the treatment of patients with renal cell carcinoma,
with innovative surgical and systemic strategies revolutionising the management of this …
with innovative surgical and systemic strategies revolutionising the management of this …
[HTML][HTML] Pathological angiogenesis and inflammation in tissues
The role of angiogenesis in the growth of organs and tumors is widely recognized. Vascular–
organ interaction is a key mechanism and a concept that enables an understanding of all …
organ interaction is a key mechanism and a concept that enables an understanding of all …
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …